Trajenta studies prove efficacy in broad range of diabetes patients

German family-owned drug major Boehringer Ingelheim and US drug major Eli Lilly (NYSE: LLY) have released new data that reinforces the efficacy and tolerability of Trajenta (linagliptin) in people with type 2 diabetes and liver disease.

The data supports the use of linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor from Boehringer and Lilly, in a broad range of adults with type 2 diabetes. Linagliptin showed a statistically significant reduction in blood glucose in adults with type 2 diabetes and liver disease, as well as reduction in blood glucose levels in Asian people aged 65 years or older with type 2 diabetes.

Adults with type 2 diabetes aged 65 years or older and those with pre-existing liver and biliary disease are characterized by limited treatment options. With the rate of T2D rapidly growing in Asia, and the prevalence of T2D and hepatobiliary diseases being high, especially in Asian countries, effective and safe treatment options are increasingly becoming a priority. Moreover, given the major elimination of linagliptin via the entero-hepatic system, it is particularly important to further characterize the efficacy and safety of linagliptin in T2D patients with liver and biliary complications.